Latham & Watkins Advises on Artiva Biotherapeutics’ US$167 Million Initial Public Offering

Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, has announced the pricing of its upsized initial public offering of 13,920,000 shares of common stock at a price to the public of US$12 per share. All of the shares of common stock are being offered by Artiva. The gross proceeds to Artiva from the offering are expected to be approximately US$167 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Artiva. In addition, Artiva has granted the underwriters a 30-day option to purchase up to an additional 2,088,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Latham & Watkins LLP represents the underwriters in the offering, with a capital markets team led by San Diego partners Matt Bush and Cheston Larson, and counsel Anthony Gostanian, with associates Omeed Valipour, Rachel Staub, and Samantha Wang.